Building on their existing partnership since 2022, Neurimmune and AstraZeneca have inked an exclusive global collaboration and license agreement to advance an antibody targeting amyloid light chains. Neurimmune will receive an undisclosed upfront payment and milestone payments of up to $780 million..

基于自2022年以来的现有合作伙伴关系，Neurimmune和阿斯利康签署了一项独家全球合作与许可协议，以推进一种针对淀粉样轻链的抗体开发。Neurimmune将获得一笔未公开的预付款以及高达7.8亿美元的里程碑付款。

Neurimmune

神经免疫

is a clinical stage biopharmaceutical company building next generation therapeutics to address protein aggregation diseases with extensive experience in amyloid depletion. Their drug candidate N1009 is a preclinical human monoclonal antibody designed to target and deplete lambda light chain fibrils and deposits from affected tissues and organs in light chain (AL) amyloidosis, is a rare, systemic and progressive disorder caused by defective plasma cells in the bone marrow..

是一家临床阶段的生物制药公司，致力于开发下一代治疗药物以应对蛋白质聚集疾病，在淀粉样蛋白清除方面拥有丰富经验。其候选药物N1009是一种临床前人源单克隆抗体，旨在靶向并清除轻链（AL）淀粉样变性患者受影响组织和器官中的λ轻链纤维和沉积物，这是一种由骨髓中异常浆细胞引起的罕见、系统性和进行性疾病。

The extended collaboration with

扩展合作

Alexion, AstraZeneca Rare Disease

Alexion，阿斯利康罕见病部门

, grants the latter an exclusive, worldwide license to research, develop, manufacture and commercialize N1009. The collaboration will leverage Alexion's expertise in AL amyloidosis and strengths in late-stage rare disease drug development and expands upon the two companies' existing Phase III development of cliramitug, an investigational human monoclonal antibody designed to deplete amyloid deposits in ATTR-CM..

，授予后者独家的全球许可，以研究、开发、制造和商业化N1009。此次合作将利用Alexion在AL型淀粉样变性方面的专业知识及其在后期罕见病药物开发中的优势，并拓展了两家公司现有的cliramitug三期开发合作，cliramitug是一种旨在清除ATTR-CM中淀粉样蛋白沉积的实验性人源单克隆抗体。

As part of the agreement, Neurimmune will receive an undisclosed upfront payment and potential additional contingent milestone payments of up to $780 million payable upon achievement of certain development, regulatory and commercial milestones, as well as tiered royalties on net sales of any approved medicine resulting from the collaboration.

根据协议，Neurimmune将获得一笔未公开的预付款，并在达成特定开发、监管和商业里程碑时，有资格获得高达7.8亿美元的潜在额外阶段性付款，以及因合作产生的任何获批药物净销售额的分级特许权使用费。

Neurimmune will continue to be responsible for preclinical development, initial manufacturing activities and conducting the first-in-human clinical study. Alexion will be responsible for further clinical development, manufacturing, and commercialization..

Neurimmune将继续负责临床前开发、初始制造活动以及进行首次人体临床研究。Alexion将负责进一步的临床开发、制造和商业化。

'We are very pleased to build upon our collaboration with Alexion by adding this targeted fibril depleter program in AL amyloidosis. By leveraging our expertise in designing therapeutics that trigger immune-mediated clearance of disease-causing protein aggregates, we have developed a novel antibody that can, potentially, efficiently deplete amyloid light chain deposits.

“我们非常高兴能够通过在AL型淀粉样变性中增加这个靶向纤维清除程序，来进一步加强与Alexion的合作。通过利用我们在设计触发免疫介导清除致病蛋白聚集体的治疗药物方面的专业知识，我们开发了一种新型抗体，有望有效清除轻链淀粉样蛋白沉积。

NI009 exhibits broad activity against amyloids of diverse lambda light chain subtypes across patients despite the high clonal heterogeneity of the disease,' said Roger M. Nitsch, President & CEO of Neurimmune..

“NI009在患者中对多种λ轻链亚型的淀粉样蛋白表现出广泛的活性，尽管该疾病具有高度的克隆异质性，”Neurimmune公司总裁兼首席执行官罗杰·M·尼奇说道。

(Press release/RAN)

（新闻稿/随机接入网络）

0

0

Comments

评论

Back to all news

返回所有新闻

Please

请

login

登录

or

或

sign up

注册

to comment.

评论。

Commenting guidelines

评论指南

Send

发送